Part of CSPC Pharmaceutical Group Ltd., CSPC Zhongqi Pharmaceutical Technology Shijiazhuang Co., Ltd. is a company headquartered in China. The firm engages in pharmaceutical research and development.

Wockhardt Ltd. is a Global pharmaceutical and biotechnology company headquartered in Mumbai, India. The company has manufacturing plants in India, UK, Ireland, France and US, and subsidiaries in US, UK, Ireland and France. It is a global company with more than half of its revenue coming from Europe. In 2011–2012 its UK and USA sales alone were US$475 million. It has market presence in emerging markets such as Russia, Brazil, Mexico, Vietnam, Philippines, Nigeria, Kenya, Ghana, Tanzania, Uganda, Nepal, Myanmar, Sri Lanka, Mauritius, Lebanon and Kuwait. The Company has a market capitalisation of over ₹211 billion (US$3.1 billion) and an annual turnover of ₹36 billion (US$520 million). It produces formulations, biopharmaceuticals, nutrition products, vaccines and active pharmaceutical ingredients (APIs). The company employs over 8,600 people globally. Wockhardt Hospitals is a subsidiary of the Wockhardt Group.

Wuhan Qirui Pharmaceutical Co., Ltd., established on 2005-09-07, Business scope includes general items:pharmaceutical production;Pharmaceutical commissioned production;Drug import and export;Import and export;Food additive production;Drug Wholesale;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Food Additive Sales;Business Management Consulting;marketing planning;Conference and Exhibition Services;Consulting and planning service;market survey(Does not include foreign investigations);Information Consulting Service(Not including licensing information consulting services);Non-residential real estate leases(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Merck Canada, Inc., part of Merck & Co., Inc., is a company headquartered in Kirkland, QC, Canada. The firm manufactures prescription medicines, vaccines, biologic therapies and animal health products. Marwan Akar is the CEO, in this role since 1997.\nThe company says this about itself: For more than 125 years, Merck, known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases in pursuit of our mission to save and improve lives. We demonstrate our commitment to patients and population health by increasing access to health care through far-reaching policies, programs and partnerships. Today, Merck continues to be at the forefront of research to prevent and treat diseases that threaten people and animals – including cancer, infectious diseases such as HIV and Ebola, and emerging animal diseases – as we aspire to be the premier research-intensive biopharmaceutical company in the world.

Merck Sharp & Dohme Corp. engages in the research, development, and distribution of vaccines, prescription drugs, and animal health products. The company is headquartered in Whitehouse Station, NJ.

Sandoz AG, part of Novartis AG, is a company headquartered in Basel, Switzerland, that develops generic medicines and biosimilars.

Savior Lifetec Corporation (SLC) is a specialty injectable company based in Chunan, Taiwan. Their state of the art facilities are vertically integrated, capable of producing sterile API and finished dosage formulations. Their facilities comply with the highest quality standards, having passed inspections by authorities from the US, EU, and Japan. SLC also has dedicated state-of-the-art GLP compliant R&D centers for API research and pharmaceutical research.SLC's expertise in sterile crystallization and the aseptic processing of sterile powder serves as the foundation for product innovation.

Daewoong Pharmaceutical Co., Ltd (Korean: 대웅제약) is a Seoul, South Korea-based bioengineering company operating as a subsidiary of Daewoong Co., Ltd., a global health care group. Daewoong Pharmaceutical primarily engages in the manufacture of pharmaceutical products in South Korea, including prescription and over-the-counter healthcare products.

Shenzhen Haibin Pharmaceutical Co., Ltd., a subsidiary of Joincare Pharmaceutical Group Industry Co., Ltd., is a Chinese company located in Shenzhen that manufactures and sells pharmaceutical products. You Guo Xie is the current CEO of the firm.

Jiangsu Desano Pharmaceutical Co. Ltd. is a Chinese private company located in Liyang. The firm provides pharmaceutical preparation services.

Xuanzhu Biopharmaceutical Co., Ltd. engages in the research and development of chemical and biological drugs. Its products include small molecular chemical drugs, monoclonal antibodies, bispecific antibodies, and antibody conjugated drugs. The company was founded in 2002 and is headquartered in Shijiazhuang, China.

Ranbaxy Laboratories Limited, a pharmaceutical company, produces a range of generic medicines. The company has a presence in 49 countries, manufacturing facilities in 11 countries and serves customers in approximately 125 countries. Products The company manufactures and markets generic pharmaceuticals, value added generic pharmaceuticals, branded generics, active Pharmaceuticals (API) and intermediates. Its product basket of approximately 5,000 SKUs available in approximately 125 countries worldwide, encompasses a therapeutic mix covering a majority of the chronic and acute segments. Research & Development The company offers value added formulations based on its Novel Drug Delivery System (NDDS) and New Chemical Entity (NCE) research outcomes. Novel Drug Delivery Systems (NDDS): The company's NDDS focus is mainly on the development of New Drug Applications (NDA) / Abbreviated New Drug Applications (ANDAs) of oral controlled- release products for the regulated markets. Ranbaxy's in-house NDDS programs are primarily focused on the oral segment. Inhalation (patented devices) and trans-dermal (patented adhesive polymers) programs are also being pursued through collaborations. In the oral NDDS space, Ranbaxy has developed four platform technologies namely Gastro Retentive, Modified Matrix, Multiparticulate and AeroGel. New Drug Discovery Research (NDDR): The company's NDDR program focuses on select therapeutic segments of Infectious diseases, Metabolic diseases, Inflammatory/ Respiratory disease and Oncology. The company has 8-10 programs in the area of NDDR. For Arterolane (potential Anti-malarial candidate), the company has obtained approval from the Drug Controller General of India to initiate Phase III human clinical trials in India. The company is also profiling DPP-IV Inhibitors (Di-Peptidyl Peptidase IV Inhibitors) for Type-2-diabetes, a selective Phosphodiesterase 4-b inhibitor for COPD and Asthma, and a novel antibiotic antibacterial for Community Acquired Respiratory Tract Infection. Under an alliance with an academic institution in India, various medicinal plants are being evaluated as potential sources for novel pharmaceutical agents. The company also has collaborative research projects with other academic institutions in India in the area of Respiratory and Infectious disease. Significant Events In June 2008, Ranbaxy entered into an alliance with Daiichi Sankyo Company Ltd., to create a generic pharmaceutical powerhouse. On September 17, 2009, Ranbaxy Laboratories Ltd. has entered into a strategic in-licensing agreement for the Indian market with Medy-Tox Inc. for its cosmetic product, Neuronox. Neuronox is a botulinum toxin type A complex (100 Units) pharmaceutical manufactured by Medy-Tox. History Ranbaxy Laboratories Limited was founded in 1961.

Shanghai Acrono Pharmaceutical Group Co., Ltd., established on 1998-08-14, Business scope includes research and development of pharmaceutical products and biotechnology products,Pilot test for R&D projects,Transfer of self-owned R&D results,Provide relevant technical support and technical services,Import and export of goods and technology(without distribution)business. [Items subject to approval by law,Business activities can only be carried out after approval by relevant departments]

Established in 1992 as an export-oriented unit (EOU), Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is a vertically integrated company spanning the entire pharmaceutical value chain from discovery to delivery with established credentials in research, manufacturing and marketing. We today rank among the top 15 pharmaceutical companies in India and enjoy a multi-therapeutic presence across segments like anti-infectives, anti-inflammatory, central nervous system (CNS), cardio vascular segment (CVS), nutraceuticals and other oral and sterile products. Their pharmaceutical solutions include active pharmaceutical ingredients (API), finished dosage forms, new drug discovery (NDD), novel drug delivery systems (NDDS) and contract research and manufacturing services (CRAMS). They are globally present across 70+ countries through alliances, joint ventures and partnerships with globally reputed majors.

Tianjin Jingye Fine Chemical Co., Ltd., established on 2001-05-25, Business scope includes Menopenem branch chainHmanufacture;Chloroformic acid-2-Ethylhexyl ester(3000Ton/year),Benzyl chloroformate(25Ton/year),Allyl chloroformate[stable](20Ton/year),Isopropyl chloroformate(90Ton/year),Octadecanoyl chloride(15Ton/year),hydrochloric acid(5488Ton/year),intermediate product:carbonyl chloride(Phosgene,5000Ton/year),carbon monoxide(1562Ton/year),Ertapenem side chain Ι production;Chemical Technology Research,to develop,Technical Advisory Services,transfer;Chemical Products(Hazardous Chemicals,Precursor Drugs Excluded)Sales;heating service;Self-owned factory lease;Industrial Wastewater Treatment(Except for hazardous waste disposal business activities);industrial water supply;practice state law,Import and export business permitted by regulations.(Hazardous Chemicals,Precursor Drugs Excluded)(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd., established on 1997-12-12, The scope of business includes the production of powder injections(Contains penicillins,Cephalosporins),Freeze-dried powder injection(Contains anti-tumor),small volume injection(Contains anti-tumor),tablet(Contains penicillins,Cephalosporins),hard capsule(Contains penicillins,Cephalosporins),Granules(Contains penicillins,Cephalosporins),oral suspension(Contains penicillins,Cephalosporins),eye drops(Hormone),nose drops,rubber plaster,Pills,Accessories,Protective materials(With infusion patch,Bandage);Sterile API(penicillin potassium,penicillin sodium,Ampicillin Sodium,ticarcillin sodium,mezlocillin sodium,Cefotaxime Sulfate,Meropenem,biapenem,Potassium clavulanate,Meropenem/Sodium carbonate,piperacillin sodium,Tazobactam Sodium,piperacillin sodium/Tazobactam Sodium,Anhydrous Sodium Carbonate,procaine penicillin,Cefazolin Sodium,cefoperazone sodium,Ceftriaxone Sodium,Ceftezole Sodium,Cefotiam Hydrochloride,Cefepime Hydrochloride/L-arginine,Cefpirome hydrochloride/Sodium carbonate,Cefodizime Sodium,Ceftizoxime Sodium,Cefmenoxime hydrochloride,Cefotaxime Sodium,cefuroxime sodium,Ceftazidime,Cefepime Hydrochloride,cefpirome sulfate,Cefathiamidine,Ceftazidime/Sodium carbonate,Cefoxitin Sodium,Cefamandole Sodium,Cefmetazole Sodium,cefminox sodium,Anhydrous Sodium Carbonate,nafcillin sodium,flucloxacillin sodium,Cefpiramide Sodium,fluoxetine sodium,Cloxacillin Sodium,benzathine penicillin,Azlocillin Sodium,Aztreonam,arginine,Sulbactam Sodium,Latamoxef sodium,Oxacillin Sodium,Amoxicillin Sodium),API(Amoxicillin,Ampicillin,Ertapenem Sodium,Cefradine,Cefixime,Cefaclor,Ceftazidime pivoxil hydrochloride,cefdinir,cefditoren pivoxil,Cefazolam Hydrochloride,metoprolol succinate,cefpodoxime axetil,Atorvastatin Calcium,repaglinide,Cinepazide Maleate,Moxifloxacin hydrochloride,pitavastatin calcium,Olmesartan medoxomil,Ornithine Aspartate,Duloxetine Hydrochloride,Entecavir,Sultacillin Tocidate,Dicloxacillin Sodium),Pharmaceutical Intermediates(7-ACA,D-7-ACA,Industrial salt containing penicillin,6-APA,7-ACT,Cefazolin,Crude Ceftriaxone,Crude meropenem,Erythromycin Thiocyanate,),immobilized penicillinGAcylase,ImmobilizedD-amino acid oxidase,immobilized glutaryl-7-ACAAcylase,cephalosporin esterase,cephalosporinsCAcylase,Agmatinase,Ornithinase,Citrullinase,Ketoreductase,glucose dehydrogenase,Proglycine dipeptide synthase,glutamate oxidase,lovastatin hydrolase,simvastatin acylase,Cefotaxime,Pharmaceutical excipient Hydroxypropyl-beta-Cyclodextrin,MAP,Pharmaceutical intermediate p-Hydroxyphenylglycine Deng salt,Phenylglycinate,p-Hydroxyphenylglycine methyl ester hydrochloride,Sodium chloride,potassium chloride;Pharmaceutical product development,Research and development of pharmaceutical technology,semi-synthetic antibiotic preparations;Sell ​​the company's own products.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Xinxiang Haibin Pharmaceutical Co., Ltd., established on 2004-08-13, Business scope includes production,Sales of pharmaceutical intermediates and raw materials(Does not contain proprietary Chinese medicines,Chinese Herbal Medicine)(Free of Hazardous Chemicals);Import and export of goods or technology(Except for the import and export of goods and technologies that are prohibited by the state or involve administrative approval).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)(The above business scope does not include the fields in the negative list of foreign investment access)(Involved in licensing projects,It should be operated after obtaining the permission of the relevant department)

Zhejiang Jiuzhou Pharmaceutical is a domestic green pharmaceutical technology company. They have developed numerous green pharmaceutical technologies with property rights due to their new medicine research and development and technology accumulation. To offer customers technical solutions and support industrial upgrading and the growth of the biomedical industry, a number of technology platforms have been established, including chiral catalysis technology, continuous technology, fluorine chemical technology, enzyme catalysis technology, photocatalysis technology, electrochemical technology, crystallisation technology, and polypeptide technology.

Hospira was an American global pharmaceutical and medical device company with headquarters in Lake Forest, Illinois. It had approximately 19,000 employees. Before its acquisition by Pfizer, Hospira was the world's largest producer of generic injectable pharmaceuticals, manufacturing generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management systems. Hospira's products are used by hospitals and alternate site providers, such as clinics, home healthcare providers and long-term care facilities. It was formerly the hospital products division of Abbott Laboratories. On September 3, 2015, Hospira was acquired by Pfizer, who subsequently sold off the medical devices portion of Hospira to ICU Medical.

Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland, and listed on the SIX Swiss Exchange (SIX: BSLN). Through the integrated research, development and commercial operations of its Swiss subsidiary Basilea Pharmaceutica International Ltd., the company focuses on providing innovative pharmaceutical products in the therapeutic areas of bacterial infections, fungal infections and oncology, targeting the medical challenge of rising resistance and nonresponse to current treatment options.